Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Obese COPD Patients
NCT03466021Phase 4Completed
- Start
- Jan 2018
- Primary completion
- May 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Transition Dyspnea Index at 40 weeks. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03466021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466021.